They enhance immune cell activity, modulate key tumour-related signalling pathways (e.g., PI3K/AKT/mTOR, MAPK, NF-κB), and improve chemotherapy efficacy by sensitising tumour cells and reducing drug resistance and toxicity. The gene discussed is AKT1; the disease is neoplasm.